Is Clozapine-induced Weight Gain Dose-dependent- Results from a Prospective Cohort Study

Abstract

Background: Antipsychotic-induced metabolic adverse effects are risk factors for cardiometabolic comorbidities. Whether dose lowering could mitigate such effects remains unclear. The present study aims to investigate the associations between clozapine doses and modifications of weight, blood pressure, blood glucose, and lipid levels. Study Design: Linear mixed-effects models of weight changes over 1 year and of variations of other metabolic parameters over 4 months were applied to a prospective cohort of 115 patients. Age- and sex-stratified analyses of weight changes were also performed. Study Results: Each 100 mg dose increment of clozapine was associated on average with a +0.48% weight increase (P =. 004) over 1 year of treatment. Weight increase was greater for treatment duration ≤3 vs >3 months (+0.84% and +0.47% per month, respectively, P 3 months (+0.54%, P =. 004) and a trend for durations ≤3 months (+0.33%, P =. 075). Dose increments of 100 mg were also associated with weight increases of +0.71% among adults (P =. 001), +1.91% among the elderly (P 300 mg/day (P =. 60). No significant effect of clozapine dose on other metabolic parameters was found. Conclusions: This study reports a modest effect of clozapine dose increases on weight gain over 1 year with differences among age categories and sexes and no dose effect on other metabolic parameters over 4 months.